In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 7, 2000, Pages 1925-1929

  Akins, Ronda L ^a,b   Rybak, Michael J ^a,b,c  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; GENTAMICIN; GLYCOPEPTIDE; HABEKACIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CELL MEMBRANE TRANSPORT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SIMULATION; DOSE RESPONSE; DRUG POTENTIATION; DRUG SCREENING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRAIN DIFFERENCE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DIBEKACIN; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENTAMICINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0033933612     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.7.1925-1929.2000     Document Type: Article

References (21)

1. Aeschlimann, J. R., E. Hershberger, and M. J. Rybak. 1999. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1914-1918.
2. Beauchamp, D., M. Pellerin, P. Gourde, M. Pettigrew, and M. G. Bergeron. 1990. Effects of daptomycin and vancomycin on tohramycin nephrotoxicity in rats. Antimicrob. Agents Chemother. 34:139-147.
3. Blaser, J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A): 125-130.
4. Centers for Disease Control and Prevention. 1997. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. Morb. Mortal. Wkly. Rep. 46:626-628, 635.
5. Flores, P. A., and S. M. Gordon. 1997. Vancomycin-resistant Staphylococcus aureus: an emerging public health threat. Clevel. Clin. J. Med. 64:527-532.
6. Hiramatsu, K. 1998. The emergence of Staphylococcus aureus with reduced susceptibility vancomycin in Japan. Am. J. Med. 104:7S-10S.
7. Hospital Infection Control Practices Advisory Committee. 1995. Recommendations for preventing the spread of vancomycin resistance. Morb. Mortal. Wkly. Rep. 44:1-13.
8. Lamp, K. C., M. J. Rybak, E. M. Bailey, and G. W. Kaatz. 1992. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother. 36:2709-2714.
9. Lee, B. L., M. Sachdeva, and H. F. Chambers. 1991. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. 35:2505-2508.
10. Moreira, B., S. Bolye-Vavra, B. L. M. deJonge, and R. Daum. 1997. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1788-1793.
11. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. Obayashi, Y., J. Fujita, S. Ichiyama, S. Hojo, K. Negayama, C. Takashima, H. Miyawaki, T. Tanabe, Y. Yamaji, K. Kawanishi, and J. Takahara. 1997. Investigation of nosocomial infection caused by arbekacin-resistant, methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 28:53-59.
13. Palmer, S. M., and M. J. Rybak. 1997. An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots. J. Antimicrob. Chemother. 39:515-518.
14. Rybak, M. J., E. M. Bailey, K. C. Lamp, and G. W. Kaatz. 1992. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob. Agents Chemother. 36:1109-1114.
15. Sieradzki, K., and A. Tomasz. 1997. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J. Bacteriol. 179:2557-2566.
16. Tenover, F. C., M. V. Lancaster, B. C. Hill, C. D. Steward, S. A. Stocker, G. A. Hancock, C. M. O'Hara, N. C. Clark, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027.
17. Thibault, N., L. Grenier, M. Simard, M. G. Bergeron, and D. Beauchamp. 1994. Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity. Antimicrob. Agents Chemother. 38:1027-1035.
18. Turco, T. F., G. P. Melko, and J. R. Williams. 1998. Vancomycin intermediate-resistant Staphylococcus aureus. Ann. Pharmacother. 32:758-760.
19. Watanabe, T., K. Ohashi, K. Matsui, and T. Kubota. 1997. Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 39:471-476.
20. Wenzel, R. P., and M. B. Edmond. 1998. Vancomycin-resistant Staphylococcus aureus: infection control considerations. Clin. Infect. Dis. 27:245-251.
21. Wood, C. A., H. C. Finkbeiner, S. J. Kohlhepp, and D. N. Gilbert. 1989. Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity. Antimicrob. Agents Chemother. 33:1280-1285.